Bruce C Schnepp
Overview
Explore the profile of Bruce C Schnepp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
641
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Spitsin S, Schnepp B, Connell M, Liu T, Dang C, Pappa V, et al.
Mol Ther Methods Clin Dev
. 2020 Jun;
17:1088-1096.
PMID: 32478124
Antibody-like molecules were evaluated with potent simian immunodeficiency virus (SIV) neutralizing properties (immunoadhesins) that were delivered by a recombinant adeno-associated virus (rAAV) vector in the SIV-infected rhesus macaque model. When...
2.
Priddy F, Lewis D, Gelderblom H, Hassanin H, Streatfield C, LaBranche C, et al.
Lancet HIV
. 2019 Mar;
6(4):e230-e239.
PMID: 30885692
Background: A preventive vaccine for HIV is a crucial public health need; adeno-associated virus (AAV)-mediated antibody gene delivery could be an alternative to immunisation to induce sustained expression of neutralising...
3.
Schnepp B, Chulay J, Ye G, Flotte T, Trapnell B, Johnson P
Hum Gene Ther
. 2015 Dec;
27(1):32-42.
PMID: 26650966
Gene augmentation therapy as a strategy to treat alpha-1 antitrypsin (AAT) deficiency has reached phase 2 clinical testing in humans. Sustained serum levels of AAT have been observed beyond one...
4.
Schnepp B, Johnson P
Microbiol Spectr
. 2015 Jun;
2(4):AID-0016-2014.
PMID: 26104192
This article focuses on a novel vaccine strategy known as vector-mediated antibody gene transfer, with a particular focus on human immunodeficiency virus (HIV). This strategy provides a solution to the...
5.
Schnepp B, Johnson P
Adv Exp Med Biol
. 2015 Mar;
848:149-67.
PMID: 25757620
This chapter discusses the emerging field of vector-mediated antibody gene transfer as an alternative vaccine for infectious disease, with a specific focus on HIV. However, this methodology need not be...
6.
Schnepp B, Johnson P
Curr Opin HIV AIDS
. 2014 Mar;
9(3):250-6.
PMID: 24638019
Purpose Of Review: In the present review, we will discuss the emerging field of vector-mediated antibody gene transfer as an alternative HIV vaccine. This approach is an improvement over classical...
7.
Clement N, Battaglioli G, Jensen R, Schnepp B, Johnson P, St George K, et al.
Emerg Infect Dis
. 2009 Jul;
15(7):1149-50.
PMID: 19624951
No abstract available.
8.
Johnson P, Schnepp B, Zhang J, Connell M, Greene S, Yuste E, et al.
Nat Med
. 2009 May;
15(8):901-6.
PMID: 19448633
The key to an effective HIV vaccine is development of an immunogen that elicits persisting antibodies with broad neutralizing activity against field strains of the virus. Unfortunately, very little progress...
9.
Schnepp B, Jensen R, Clark K, Johnson P
J Virol
. 2008 Nov;
83(3):1456-64.
PMID: 19019948
Adeno-associated virus (AAV) replication and biology have been extensively studied using cell culture systems, but there is precious little known about AAV biology in natural hosts. As part of our...
10.
Schnepp B, Jensen R, Chen C, Johnson P, Clark K
J Virol
. 2005 Nov;
79(23):14793-803.
PMID: 16282479
Infection with wild-type adeno-associated virus (AAV) is common in humans, but very little is known about the in vivo biology of AAV. On a molecular level, it has been shown...